BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Australia's Inventia announces groundbreaking advancement in 3D cell culture technology

28 January 2025 | News

To revolutionise high-throughput 3D cell culture for drug discovery and disease research

Inventia Life Science, an innovator in 3D cell culture technologies, has announced the launch of RASTRUM Allegro, a groundbreaking advancement in 3D cell culture technology designed to accelerate drug discovery and disease research with unprecedented scalability, reproducibility, and efficiency.

RASTRUM Allegro addresses key challenges faced by researchers, including the need for consistent, scalable 3D models that generate meaningful insights and limited availability of patient-derived cells, which are often challenging to expand and maintain in traditional 3D culture environments. This next-generation platform empowers scientists to create complex, reproducible 3D cell models with minimal hands-on time, making advanced biology more accessible.

The product makes it easier than ever to create high-throughput 3D cell culture assays that offer both speed and affordability. By significantly reducing per-sample costs, researchers can explore more variables and gain meaningful insights while ensuring data consistency across experiments.

RASTRUM Allegro is already transforming workflows for drug screening and disease modeling. Cameron Ferris, PhD, COO at Inventia Life Science, highlighted its impact stating, "For years, researchers had to choose between biological complexity and scalability. RASTRUM Allegro eliminates that trade-off, enabling high-throughput 3D cell culture while maintaining reproducibility on par with 2D systems. This shift empowers researchers to explore complex disease phenotypes confidently and scale their experiments for more meaningful insights."